Open Payments

ADVENTIST HEALTH GLENDALE

Type
Teaching hospital
Where
Glendale, CA
Medicare CCN
050239
Received
$832,635 in 63 records, 2024 ($18,865 general, $813,770 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment3$18,865
2024Research payment60$813,770

By company

CompanyRecordsAmountYears
PFIZER INC.18$534,3362024
Novartis Pharmaceuticals Corporation1$152,2882024
Janssen Research & Development, LLC27$65,0622024
Genentech, Inc.3$27,3592024
Premia Spine, Ltd.5$21,7482024
AngioDynamics, Inc.1$13,0002024
Dilon Technologies, Inc.5$11,9752024
Aesculap Implant Systems, LLC1$3,9002024
Stryker Corporation1$1,9652024
Cerapedics Inc.1$1,0002024

By nature of payment

NatureRecordsAmount
Research payment60$813,770
Long term medical supply or device loan2$14,965
Debt forgiveness1$3,900

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31AngioDynamics, Inc.$13,000Long term medical supply or device loanIn-kind items and servicesSolero Device, Oncology2024
2024-12-31Stryker Corporation$1,965Long term medical supply or device loanIn-kind items and servicesSDC3 Device, ENDOSCOPY2024
2024-12-18Janssen Research & Development, LLC$2,037Research paymentCash or cash equivalent70033093STR30012024
2024-12-16Janssen Research & Development, LLC$798Research paymentCash or cash equivalent70033093STR30012024
2024-12-11Janssen Research & Development, LLC$920Research paymentCash or cash equivalent70033093STR30012024
2024-11-21PFIZER INC.$44,430Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-11-21PFIZER INC.$44,430Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-11-18Janssen Research & Development, LLC$1,844Research paymentCash or cash equivalent70033093STR30012024
2024-11-08PFIZER INC.$1,714Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-10-26PFIZER INC.$9,162Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST2024
2024-10-21Janssen Research & Development, LLC$3,746Research paymentCash or cash equivalent70033093STR30012024
2024-10-18Janssen Research & Development, LLC$2,448Research paymentCash or cash equivalent70033093STR30012024
2024-10-16PFIZER INC.$150Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-10-05PFIZER INC.$22,370Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-09-25Janssen Research & Development, LLC$2,642Research paymentCash or cash equivalent70033093STR30012024
2024-09-20Janssen Research & Development, LLC$530Research paymentCash or cash equivalent70033093STR30012024
2024-09-13Janssen Research & Development, LLC$2,543Research paymentCash or cash equivalent70033093STR30012024
2024-08-29PFIZER INC.$44,430Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-08-29PFIZER INC.$44,430Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-08-28PFIZER INC.$2,219Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-08-23Janssen Research & Development, LLC$4,346Research paymentCash or cash equivalent70033093STR30012024
2024-08-22Genentech, Inc.$4,050Research paymentCash or cash equivalentTecentriq Biological, BioOncologyA PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC2024
2024-08-21Janssen Research & Development, LLC$1,115Research paymentCash or cash equivalent70033093STR30012024
2024-08-05Cerapedics Inc.$1,000Research paymentCash or cash equivalentI-FACTOR PEPTIDE ENHANCED BONE GRAFT Device, PEPTIDE ENHANCED BONE GRAFTAspire Trial2024
2024-07-24Janssen Research & Development, LLC$4,975Research paymentCash or cash equivalent70033093STR30012024
2024-07-09Genentech, Inc.$20,081Research paymentCash or cash equivalentTecentriq Biological, BioOncologyA PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC2024
2024-07-01Premia Spine, Ltd.$3,781Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2024
2024-07-01Premia Spine, Ltd.$50Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2024
2024-06-25Janssen Research & Development, LLC$992Research paymentCash or cash equivalent70033093STR30012024
2024-06-19Janssen Research & Development, LLC$3,831Research paymentCash or cash equivalent70033093STR30012024
2024-06-07Janssen Research & Development, LLC$1,115Research paymentCash or cash equivalent70033093STR30012024
2024-06-03Janssen Research & Development, LLC$886Research paymentCash or cash equivalent70033093STR30012024
2024-05-29PFIZER INC.$2,018Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-05-28PFIZER INC.$59,240Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-05-28PFIZER INC.$59,240Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-05-26PFIZER INC.$59,240Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-05-22Janssen Research & Development, LLC$5,473Research paymentCash or cash equivalent70033093STR30012024
2024-04-30PFIZER INC.$911Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-04-19Janssen Research & Development, LLC$2,130Research paymentCash or cash equivalent70033093STR30012024
2024-04-15Janssen Research & Development, LLC$1,666Research paymentCash or cash equivalent70033093STR30012024
2024-04-15Premia Spine, Ltd.$1,204Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2024
2024-04-08Janssen Research & Development, LLC$1,593Research paymentCash or cash equivalent70033093STR30012024
2024-04-02PFIZER INC.$7,053Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-03-22Janssen Research & Development, LLC$8,363Research paymentCash or cash equivalent70033093STR30012024
2024-03-22Dilon Technologies, Inc.$3,375Research paymentCash or cash equivalentMARGINPROBE PROBE Device, MARGIN ASSESSMENTMarginProbe 2.0 Data Collection Protocol2024
2024-03-14PFIZER INC.$44,430Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-03-14PFIZER INC.$44,430Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-03-14PFIZER INC.$44,430Research paymentIn-kind items and servicesTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-03-13Janssen Research & Development, LLC$394Research paymentCash or cash equivalent70033093STR30012024
2024-03-06Janssen Research & Development, LLC$224Research paymentCash or cash equivalent70033093STR30012024
2024-02-21Janssen Research & Development, LLC$1,596Research paymentCash or cash equivalent70033093STR30012024
2024-02-16Dilon Technologies, Inc.$950Research paymentCash or cash equivalentMARGINPROBE PROBE Device, MARGIN ASSESSMENTMarginProbe 2.0 Data Collection Protocol2024
2024-02-15Dilon Technologies, Inc.$3,775Research paymentCash or cash equivalentMARGINPROBE PROBE Device, MARGIN ASSESSMENTMarginProbe 2.0 Data Collection Protocol2024
2024-02-14Aesculap Implant Systems, LLC$3,900Debt forgivenessCash or cash equivalent2024
2024-02-12Genentech, Inc.$3,228Research paymentCash or cash equivalentHerceptin Biological, BioOncologyT DM1 Atezolizumab in high risk HER2 patients with residual disease2024
2024-02-02Dilon Technologies, Inc.$1,350Research paymentCash or cash equivalentMARGINPROBE PROBE Device, MARGIN ASSESSMENTMarginProbe 2.0 Data Collection Protocol2024
2024-02-02Janssen Research & Development, LLC$784Research paymentCash or cash equivalent70033093STR30012024
2024-01-30Novartis Pharmaceuticals Corporation$152,288Research paymentCash or cash equivalentA Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus2024
2024-01-25Dilon Technologies, Inc.$2,525Research paymentCash or cash equivalentMARGINPROBE PROBE Device, MARGIN ASSESSMENTMarginProbe 2.0 Data Collection Protocol2024
2024-01-22Janssen Research & Development, LLC$7,532Research paymentCash or cash equivalent70033093STR30012024
2024-01-12Janssen Research & Development, LLC$539Research paymentCash or cash equivalent70033093STR30012024
2024-01-04Premia Spine, Ltd.$7,754Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2024
2024-01-02Premia Spine, Ltd.$8,958Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Los Angeles CountyGlendale city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Glendale, CA, county Los Angeles County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Glendale, CA
County
Los Angeles County, CA
State
California
Population B01003190,7489,808,66739,287,377
Population, 2020 census P1196,54310,014,00939,538,223
Median age B0100241.438.237.9
Under 18 B0100118.4%20.6%22.0%
65 and over B0100119.0%15.2%15.7%
Households B1100172,5733,416,44913,548,091
Foreign born B0500251.5%33.4%27.0%
Median household income B19013$88,393$90,112$99,122
Median family income B19113$102,513$101,573$113,346
Per capita income B19301$49,653$45,792$49,513
Poverty rate B1700112.9%13.7%12.0%
Unemployment rate B230258.3%7.3%6.6%
Civilian labor force B23025100,5925,200,65620,068,466
Mean commute (minutes) B0801327.130.428.7
Bachelor's degree or higher B1500347.2%36.0%37.1%
Housing units B2500177,7833,650,46614,644,735
Owner-occupied B2500335.2%45.9%55.9%
Renters B2500364.8%54.1%44.1%
Median home value B25077$1,102,300$834,200$734,700
Median gross rent B25064$2,182$1,954$2,036
White, not Hispanic B0300262.8%24.7%33.8%
Black B030021.4%7.4%5.2%
Hispanic or Latino B0300218.1%48.4%40.2%
Asian B0300212.8%14.9%15.3%
American Indian and Alaska Native B030020.0%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Glendale, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.